Pharmaceuticals 2013, 6(1), 25-31; doi:10.3390/ph6010025
Article

Stability of Recombinant Tissue Plasminogen Activator at −30 °C over One Year

1 College of Pharmacy, King Saud bin Abdulaziz University for Health Sciences, Riyadh 11426, Saudi Arabia 2 National Guard Health Affairs, King Abdulaziz Medical City, Riyadh, 11426, Saudi Arabia
Received: 12 November 2012; in revised form: 24 December 2012 / Accepted: 26 December 2012 / Published: 2 January 2013
PDF Full-text Download PDF Full-Text [202 KB, uploaded 2 January 2013 16:03 CET]
Abstract: Recombinant tissue plasminogen activator (rt-PA) is used to restore patency and avoid inadvertent removal of peripheral and central venous catheters. rt-PA was reconstituted (1 mg/mL) then cryopreserved at −30 °C for 1, 2, 3, 6, 8, and 12 months and, then its stability was determined. After cryopreservation for one and two months, rt-PA kept more than 95% of its activity compared to standard samples, while cryopreservation for three months caused 8% loss of activity. However, after cryopreservation for six months or more, rt-PA retained only 87.5% or less activity compared to standard samples. Therefore, it is recommended that reconstituted rt-PA be cryopreserved at −30 °C for a maximum period of three months.
Keywords: cryopreservation; fibrinolysis; stability; tissue plasminogen activator

Article Statistics

Load and display the download statistics.

Citations to this Article

Cite This Article

MDPI and ACS Style

Alkatheri, A. Stability of Recombinant Tissue Plasminogen Activator at −30 °C over One Year. Pharmaceuticals 2013, 6, 25-31.

AMA Style

Alkatheri A. Stability of Recombinant Tissue Plasminogen Activator at −30 °C over One Year. Pharmaceuticals. 2013; 6(1):25-31.

Chicago/Turabian Style

Alkatheri, Abdulmalik. 2013. "Stability of Recombinant Tissue Plasminogen Activator at −30 °C over One Year." Pharmaceuticals 6, no. 1: 25-31.

Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert